Marc Gleeson

With over 25 years of commercialization experience in the pharmaceutical and biotech industries, with 19 years of those years working in Ophthalmology, Marc Gleeson serves as Chief Executive Officer of Azura Ophthalmics.

Prior to Azura Ophthalmics, Marc was Vice President of Global Marketing for Oculeve, a San Francisco start-up that developed the first neurostimulatory device for the treatment of dry eye disease, which was acquired by Allergan in 2015. Prior to his work at Oculeve, Marc spent 14 years at Allergan working across the Asia-Pacific region and the US as Vice President of Global Strategic Marketing for Eye Care. In this role, Marc lead the early commercial development of all internal R&D projects across the Ophthalmic franchise as well as focused on in-licensing or acquiring external assets. He also worked across the retina, dry eye, glaucoma, and ocular surface disease franchises at Allergen.

Marc served on the Board of Elastagen Pty Ltd, an Australian start-up that developed medical aesthetic treatments before being acquired by Allergan Inc. Prior to moving to the US with Allergan, Marc was responsible for both the Ophthalmology and Botox Cosmetic at Allergan Australia and New Zealand.